Press Room

July 23, 2014

bioTheranostics Names Ramesh Hariharan as Vice President of Marketing

FOR IMMEDIATE RELEASE…July 23, 2014…SAN DIEGO…bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, today announced the addition of Ramesh Hariharan, Ph.D., to the company’s senior management team as vice president of marketing. Hariharan will lead bioTheranostics’ commercial development and marketing efforts for the company’s suite of molecular diagnostic tests, which address significant unmet medical needs in cancer care.

Richard Ding, CEO of bioTheranostics, said, “Ramesh is a highly regarded and accomplished executive who brings significant industry experience to bioTheranostics. He will be instrumental in spearheading market and product strategy development, corporate positioning, and commercialization efforts for our breakthrough genomic solutions, as well as developing new partnerships and relationships that showcase our commitment to providing high-value diagnostic tests for cancer patients and their physicians.”

Hariharan brings more than 17 years of leadership experience in diagnostics and biotechnology marketing and sales. Prior to joining bioTheranostics, he was head of the Women’s Health & Pain franchise at AbbVie, and he also held senior-level positions at Abbott, Novartis, and McKinsey & Company spanning several therapeutic areas including oncology, vaccines, and nephrology. Hariharan earned a bachelor’s degree in chemical engineering from the Indian Institute of Technology, Bombay, a doctorate in chemical engineering from Princeton University, and a master’s degree in business administration from Massachusetts Institute of Technology’s Sloan School of Management.

“It is exciting to join a company with two compelling and innovative product platforms that fulfill large unmet clinical needs for cancer patients and physicians,” Hariharan said. “Our Breast Cancer IndexSM is uniquely positioned to make a positive impact on practice management and treatment decisions, as it is the only test that can identify patients at high risk for late breast cancer recurrence, as well as those who would benefit from extended endocrine therapy. Similarly, our patient- and practice-centric bioT3 Metastatic Cancer Solution is unique because it provides comprehensive information for definitive diagnosis and biomarker-driven treatment options across the full continuum of metastatic cancer.”

About Biotheranostics

bioTheranostics, Inc., is the leading solution provider for early stage breast cancer and a broad range of metastatic cancers, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the Breast Cancer IndexSM, which quantifies risk of early and late recurrence of estrogen receptor-positive breast cancer, and the bioT3 Metastatic Cancer Solution suite of tests, which includes CancerTYPE ID® and CancerTREATMENT ID. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at biotheranostics.com.